Literature DB >> 7722132

Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans.

F D Murgatroyd1, A K Slade, S M Sopher, E Rowland, D E Ward, A J Camm.   

Abstract

OBJECTIVES: This study investigated the efficacy and tolerability of low energy shocks for termination of atrial fibrillation in patients, using an endocardial electrode configuration that embraced both atria.
BACKGROUND: In animals, low energy biphasic shocks delivered between electrodes in the coronary sinus and right atrium have effectively terminated atrial fibrillation. If human defibrillation thresholds are sufficiently low, atrial defibrillation could be achieved in conscious patients using an implanted device.
METHODS: Twenty-two consecutive patients with stable atrial fibrillation were studied during electrophysiologic testing. Biphasic R wave synchronous shocks were delivered between large surface area electrodes in the coronary sinus and high right atrium, using a step-up voltage protocol starting at 10 or 20 V and increasing to a maximum of 400 V. Patients were conscious at the start of the study and were asked to report on symptoms but were sedated later if shocks were not tolerated.
RESULTS: Cardioversion was achieved in all 19 patients who completed the study, with a mean (+/- SD) leading-edge voltage of 237 +/- 55 V (range 140 to 340) and mean energy of 2.16 +/- 1.02 J (range 0.7 to 4.4). The mean maximal shock delivered without sedation was 116 +/- 51 V (range 60 to 180). No proarrhythmia or mechanical complications occurred.
CONCLUSIONS: The delivery of biphasic R wave synchronous shocks between the high right atrium and coronary sinus can terminate atrial fibrillation with very low energies. General anaesthesia is not required, and a minority of fully conscious patients are able to tolerate this method of cardioversion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7722132     DOI: 10.1016/0735-1097(94)00555-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

Review 1.  New devices and hybrid therapies and new devices for treatment of atrial fibrillation.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

2.  External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements.

Authors:  G L Botto; A Politi; W Bonini; T Broffoni; R Bonatti
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

3.  Clinical feasibility of low energy internal atrial cardioversion with a three-electrode configuration in patients with unsuccessful conventional configurations.

Authors:  G Benedini; A Gardini; T Toselli; G Antonioli; G Guardigli; G Saccomanno; M Marini
Journal:  J Interv Card Electrophysiol       Date:  2000-04       Impact factor: 1.900

Review 4.  Optimizing atrial defibrillation.

Authors:  A Prakash; S Saksena
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

Review 5.  New concepts in atrial defibrillation.

Authors:  G M Ayers
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

6.  eHEART: www.heartjnl.com.

Authors: 
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

7.  Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol.

Authors:  H F Tse; C P Lau; G M Ayers
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

8.  Transvenous cardioversion of atrial fibrillation using low-energy shocks.

Authors:  A G Socas; P Ricard; V Taramasco; M Guenoun; S Lévy
Journal:  J Interv Card Electrophysiol       Date:  1997-09       Impact factor: 1.900

9.  Atrial fibrillation: the last challenge in interventional electrophysiology.

Authors:  F D Murgatroyd; A J Camm
Journal:  Br Heart J       Date:  1995-09

10.  Treatment satisfaction of internal versus external cardioversion in patients with chronic atrial fibrillation--a randomized, prospective, 28-day follow-up study.

Authors:  Karl-Heinz Ladwig; Günter Lehmann; Birgitt Marten-Mittag; Heidi Simon; Eckhard Alt
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.